|
1000
|
Abstract/Summary
|
-
<jats:title>Abstract</jats:title><jats:sec>
<jats:title>Background</jats:title>
<jats:p>CLN3 disease (also known as CLN3 Batten disease or Juvenile Neuronal Ceroid Lipofuscinosis) is a rare pediatric neurodegenerative disorder caused by biallelic mutations in <jats:italic>CLN3</jats:italic>. While extensive efforts have been undertaken to understand CLN3 disease etiology, pathology, and clinical progression, little is known about the impact of CLN3 disease on parents and caregivers. Here, we investigated CLN3 disease progression, clinical care, and family experiences using semi-structured interviews with 39 parents of individuals with CLN3 disease. Analysis included response categorization by independent observers and quantitative methods.</jats:p>
</jats:sec><jats:sec>
<jats:title>Results</jats:title>
<jats:p>Parents reported patterns of disease progression that aligned with previous reports. Insomnia and thought- and mood-related concerns were reported frequently. “Decline in visual acuity” was the first sign/symptom noticed by <jats:italic>n</jats:italic> = 28 parents (70%). A minority of parents reported “behavioral issues” (<jats:italic>n</jats:italic> = 5, 12.5%), “communication issues” (<jats:italic>n</jats:italic> = 3, 7.5%), “cognitive decline” (<jats:italic>n</jats:italic> = 1, 2.5%), or “seizures” (<jats:italic>n</jats:italic> = 1, 2.5%) as the first sign/symptom. The mean time from the first signs or symptoms to a diagnosis of CLN3 disease was 2.8 years (SD = 4.1). Misdiagnosis was common, being reported by <jats:italic>n</jats:italic> = 24 participants (55.8%). Diagnostic tests and treatments were closely aligned with observed symptoms. Desires for improved or stabilized vision (top therapeutic treatment concern for <jats:italic>n</jats:italic> = 14, 32.6%), cognition (<jats:italic>n</jats:italic> = 8, 18.6%), and mobility (<jats:italic>n</jats:italic> = 3, 7%) dominated parental concerns and wishes for therapeutic correction. Family impacts were common, with <jats:italic>n</jats:italic> = 34 (81%) of respondents reporting a financial impact on the family and <jats:italic>n</jats:italic> = 20 (46.5%) reporting marital strain related to the disease.</jats:p>
</jats:sec><jats:sec>
<jats:title>Conclusions</jats:title>
<jats:p>Collectively, responses demonstrated clear patterns of disease progression, a strong desire for therapies to treat symptoms related to vision and cognition, and a powerful family impact driven by the unrelenting nature of disease progression.</jats:p>
</jats:sec>
|
